Summary

This article discusses discussed major advances in the treatment of human epidermal growth factor 2 (HER2)-positive breast cancer in the past decade, the current state of adjuvant therapy for HER2-positive breast cancer, as well as the therapeutic implications of neoadjuvant therapy for HER2-positive breast cancer.